Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis

Pre‐clinical congestion markers of worsening heart failure (HF) can be monitored by devices and may support the management of patients with HF. We aimed to assess whether congestion‐guided HF management according to device‐based remote monitoring strategies is more effective than standard therapy.

[1]  D. Burkhoff,et al.  Remote Cardiac Monitoring in Patients With Heart Failure: A Review. , 2021, JAMA cardiology.

[2]  J. Boehmer,et al.  Letter to the editor to update the article “Remote monitoring for heart failure using implantable devices: a systematic review, meta-analysis, and meta-regression of randomized controlled trials” , 2021, Heart Failure Reviews.

[3]  Natasha Meunier-McVey,et al.  2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure , 2021, EMJ Cardiology.

[4]  M. Barbarawi,et al.  Efficacy of remote physiological monitoring-guided care for chronic heart failure: an updated meta-analysis , 2021, Heart Failure Reviews.

[5]  J. Boehmer,et al.  Remote monitoring for heart failure using implantable devices: a systematic review, meta-analysis, and meta-regression of randomized controlled trials , 2021, Heart Failure Reviews.

[6]  Akshay S. Desai,et al.  Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial , 2021, The Lancet.

[7]  T. Nieminen,et al.  Non‐invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta‐analysis , 2021, ESC heart failure.

[8]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[9]  Kipp W. Johnson,et al.  Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management , 2020, Nature Reviews Cardiology.

[10]  R. Varadhan,et al.  Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses , 2020, Canadian Medical Association Journal.

[11]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[12]  Gerta Rücker,et al.  How to perform a meta-analysis with R: a practical tutorial , 2019, Evidence-Based Mental Health.

[13]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[14]  Akshay S. Desai,et al.  Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis , 2019 .

[15]  G. Ewald,et al.  Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. , 2018, Journal of cardiac failure.

[16]  P. Sobotka,et al.  Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial , 2018, ESC heart failure.

[17]  G. Hindricks,et al.  Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST) , 2017, European heart journal.

[18]  S. Anker,et al.  Remote haemodynamic‐guided care for patients with chronic heart failure: a meta‐analysis of completed trials , 2017, European journal of heart failure.

[19]  Haran Burri,et al.  Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE‐CARE multicentre randomized controlled trial , 2017, European journal of heart failure.

[20]  P. Thokala,et al.  The cost‐effectiveness of real‐time pulmonary artery pressure monitoring in heart failure patients: a European perspective , 2017, European journal of heart failure.

[21]  M. Zile,et al.  Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. , 2017, Circulation. Heart failure.

[22]  M. Turakhia,et al.  Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. , 2016, JACC. Heart failure.

[23]  Michael Böhm,et al.  Fluid status telemedicine alerts for heart failure: a randomized controlled trial. , 2016, European heart journal.

[24]  R. Hunter,et al.  The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study). , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  L. Stevenson,et al.  Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial , 2016, The Lancet.

[26]  G. Hasenfuss,et al.  A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  E. Heist,et al.  Accurate monitoring of intravascular fluid volume: A novel application of intrathoracic impedance measures for the guidance of volume reduction therapy , 2014, International journal of cardiology. Heart & vasculature.

[28]  William T. Abraham,et al.  Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[29]  Hhs Centers for Medicare Medicare Services.  Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2015 rates; quality reporting requirements for specific providers; reasonable compensation equivalents for physician services in exclud , 2014, Federal register.

[30]  Michael Borenstein,et al.  Meta-Analysis and Subgroups , 2013, Prevention Science.

[31]  Robert O. Bonow,et al.  Rehospitalization for heart failure: problems and perspectives. , 2013, Journal of the American College of Cardiology.

[32]  L. Tavazzi,et al.  Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. , 2011, European heart journal.

[33]  M. Gold,et al.  Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. , 2011, Congestive heart failure.

[34]  Ayesha Hasan,et al.  Telemonitoring in chronic heart failure. , 2011, European heart journal.

[35]  P. Adamson,et al.  Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: New insights from continuous monitoring devices , 2009, Current heart failure reports.

[36]  P. Bagos,et al.  Mixed-Effects Poisson Regression Models for Meta-Analysis of Follow-Up Studies with Constant or Varying Durations , 2009 .

[37]  M. Zile,et al.  Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.

[38]  M. Zile,et al.  Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. , 2008, Journal of the American College of Cardiology.

[39]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[40]  Jagmeet P. Singh,et al.  Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). , 2005, Journal of the American College of Cardiology.

[41]  C. O’loughlin,et al.  Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis? , 2005, European journal of heart failure.

[42]  C. Lau,et al.  Intrathoracic Impedance Monitoring in Patients With Heart Failure: Correlation With Fluid Status and Feasibility of Early Warning Preceding Hospitalization , 2005, Circulation.

[43]  W. Abraham,et al.  Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device , 2004, Circulation.

[44]  L. Tavazzi,et al.  Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). , 2001, The American journal of cardiology.